Key Highlights

  • Third-quarter Revenue at SS Innovations International (NASDAQ:SSII) fell 51% to USD 6.3 million from USD 12.8 million, with system sales down to USD 4.7 million from USD 11.7 million.
  • Net loss widened to USD 5.7 million from USD 3.7 million, as Research and Development spending tripled to USD 2.5 million.
  • Nine-month revenue rose 12% to USD 31.4 million, with 54 SSi Mantra systems sold, while the nine-month net loss was USD 12.0 million.
  • A USD 20.0 million secured convertible note closed on October 9, 2026, after cash of USD 8.1 million and restricted cash of USD 10.5 million at September 30.

System Sales Drop to USD 4.7 Million After a Heavy Prior-Year Quarter

SS Innovations International (NASDAQ:SSII) filed its Quarterly Report on November 16, 2026. Revenue was USD 6.3 million against USD 12.8 million a year earlier, as system sales fell to USD 4.7 million from USD 11.7 million. The company, based in Gurugram, India, develops and sells the SSi Mantra surgical robotic system and SSi Mudra instruments for cardiac and other procedures. It sold 11 systems in the quarter and 54 over nine months. Instrument sales rose to USD 1.0 million and warranty sales to USD 0.6 million. Gross Profit halved to USD 3.1 million. For nine months, revenue was USD 31.4 million versus USD 28.0 million, and gross profit rose to USD 15.6 million.

Research Spending Triples as U.S. and EU Approvals Are Pursued

Research and development expense climbed to USD 2.5 million from USD 0.8 million, while selling, general and administrative expense eased to USD 4.2 million because the prior year included one-time public offering fees. Stock Compensation was USD 2.2 million. Operating loss was USD 6.1 million versus USD 1.8 million. Interest expense was USD 0.5 million, the income tax line swung to a USD 0.2 million benefit from a USD 1.8 million expense, and net loss was USD 5.7 million, or USD 0.03 a share. Nine-month net loss reached USD 12.0 million, against USD 9.7 million. The company filed for U.S. FDA and EU CE mark approval in 2025, and those reviews continue in 2026. Management says results also depend on winning approvals in regulated markets.

USD 20 Million Convertible Note Follows a Going-Concern Warning

Cash and equivalents were USD 8.1 million, up from USD 3.2 million at year-end, with USD 10.5 million of restricted cash held as bank security. Short-term borrowings were USD 16.9 million, total liabilities USD 46.6 million and Equity USD 49.9 million. Nine-month operating cash outflow was USD 12.9 million, funded by USD 18.4 million of private Placement proceeds and borrowings. On October 9, the company issued a secured convertible note with USD 21.0 million of principal for USD 20.0 million, carrying 8.75% interest and a 36-month term. The filing still says substantial doubt exists about continuing as a going concern, and notes a USD 50 million at-the-market program with no shares sold. A new chief financial officer started November 6, 2026, and the company said it plans to raise more Capital during the rest of the year.

Where Things Stand

Lumpy system deliveries explain the drop, and the nine-month trend is still up. SS Innovations International (NASDAQ:SSII) sold 11 systems in the quarter versus a much larger prior-year batch, so revenue halved, yet 54 systems over nine months lifted revenue 12%. Losses widened on higher research spending, and the filing keeps going-concern language despite the USD 20.0 million note. Next markers are fourth-quarter system placements, FDA and CE mark decisions, use of note proceeds, and conversion or Redemption terms on the debt.